A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer.

BACKGROUND

Proton pump inhibitors (PPIs) are commonly prescribed drugs in clinical practice, mainly for the treatment of Helicobacter pylori infection and gastroesophageal reflux disease (GERD). With the application of PPIs, doctors have found a variety of adverse reactions related to it, with gastric cancer being the most serious. Our aim is to investigate whether the use of PPIs increases the probability of gastric cancer.

METHODS

By searching PubMed, EMBASE, the Cochrane Library and Web of science, references related to PPIs and gastric cancer were selected, and Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the included references and analyze their bias. Then stataSE-64 was used for statistical analysis. The above processes were independently searched and evaluated by 2 researchers.

RESULTS

The use of PPIs significantly increased the incidence of gastric cancer (RR = 1.75, 95% CI: 1.48-2.07, P = .000).

CONCLUSION

Long-term use of PPIs may increase the incidence of gastric cancer.